OncoMatch/Clinical Trials/NCT07023588
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
Is NCT07023588 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Venetoclax for acute myeloid leukemia (aml).
Treatment: Venetoclax — A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: BCL2 inhibitor (venetoclax)
Prior venetoclax treatment
Lab requirements
Kidney function
creatinine clearance ≥ 50 mL/min (Cockcroft-Gault or 24-hour urine collection)
Liver function
AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN (unless considered due to leukemia infiltration)
Renal function with creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula or measured by 24-hour urine collection). Liver function with AST ≤ 2.5 × ULN; ALT ≤ 2.5 × ULN; Total bilirubin ≤ 1.5 × ULN (unless considered due to leukemia infiltration). Significant hepatic or renal dysfunction exceeding the inclusion criteria limits [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07023588 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages